CD47, a ubiquitously expressed innate immune checkpoint receptor that serves as a universal "don't eat me" signal of phagocytosis, is often up-regulated by hematological and solid cancers to evade immune surveillance. Development of CD47-targeted modalities is hindered by the ubiquitous expression of the target, often leading to rapid drug elimination and hemotoxicity including anemia.
Introduction
The incidence of hematological malignancies has been on the rise for the last 30 years, and accounts for approximately 9% of all cancers (1) . Of the hematological malignancies, lymphoma is the most common type. B cell lymphomas are far more frequent than T-cell lymphomas accounting for around 85% of all Non-Hodgkin lymphomas (NHL). The introduction of rituximab, the first anti-CD20 monoclonal antibody (mAb), has revolutionized the management of B cell lymphomas (2) . Rituximab plus the "CHOP" (i.e., cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy regime is the frontline treatment for B cell lymphomas (3) . However, 30-60% of indolent NHL patients are resistant to rituximab at baseline and up to 50% of patients suffer relapses after anti-CD20 therapies and become refractory to their treatment (4).
Two major mechanisms underlying rituximab relapse/refractory responses are low CD20 expression levels in some lymphoma patients and downregulation of CD20 expression post anti-CD20 treatment (5, 6) . CD19, a B cell specific marker, has been considered to be a promising target to overcome the anti-CD20 resistant/refractory situation. CD19 is a transmembrane glycoprotein of the immunoglobulin (Ig) superfamily. It is expressed during different stages of B cell development, starting from pre-B cell stage till being down-regulated in early plasma cells (7) . Furthermore, CD19 is broadly expressed in B cell malignancies including those which are CD20 positive (e.g., NHL and B-chronic lymphocytic leukemia (B-CLL)) and those which may be CD20 low or negative (e.g., Bacute lymphoblastic leukemia (B-ALL)) (8) . Consistent with its broad expression spectrum in B cell malignancies, targeting CD19 with different strategies (e.g., CD3/CD19 bispecific, CD19 CAR T cells) to harness B cell killing has generated promising results in several clinical trials (9) (10) (11) .
The emergence of "checkpoint inhibitors", e.g., antibodies that block the interaction of PD-1 with its ligand PD-L1, thereby unleashing the natural brake on T-cells and boosting the immune response represent a paradigm shift in our approach to treating cancer (12) . In addition to harnessing the adaptive immune response to fight malignant cells, attention has turned to the innate immune system, in particular macrophages, a cell population which is abundant in the tumor microenvironment and which plays a specific role in phagocytosing cancer cells (13) .
Macrophages express signal regulatory protein α (SIRPα) that interacts with CD47, a ubiquitously expressed protein that mediates a "don't eat me" signal. Cancer cells have evolved to hijack this interaction by upregulating the expression of CD47 on their cell surface, thus counterbalancing prophagocytic signals and increasing the chance of evading innate immune surveillance (14) . Therefore, blockade of the CD47/SIRPα interaction represents a promising strategy to increase the phagocytic clearance of tumor cells from the body. Several mAb and fusion proteins that target this interaction are in early clinical development (clinicaltrials.gov; e.g. NCT02953509, NCT03013218, NCT02367196 and NCT02890368). One limitation of this approach is that CD47, whilst upregulated on tumor cells (15) , is also ubiquitously expressed on all cells of the body, including relatively high levels on erythrocytes and platelets (16, 17) . Monospecific agents targeting CD47 would thus be expected to exhibit poor pharmacokinetic properties due to target mediated drug disposition (TMDD) and possible side effects including anemia.
We have recently described a fully human bispecific antibody (biAb) format, the κλ-body (18) . Using this format, we generated a panel of biAb comprising a high affinity CD19 targeting arm combined with CD47 blocking arms with a range of affinities, on a human IgG1 Fc backbone to impart full effector mechanisms (19) . The resultant biAbs are able to selectively block the interaction CD47/SIRPα on CD19 + cells and induce tumor cell killing in vitro and in vivo. From the panel of biAbs, we selected the CD47 arm with the appropriate affinity needed to balance efficacy on CD19 + cells against "off-target" effects, i.e., an affinity that is weak enough to result in a fast off-rate for CD47 on non CD19 + cells.
Here we describe the preclinical characterization of NI-1701, which induces potent macrophagemediated phagocytosis of tumor cell lines and primary samples representing various B cell malignancies. We also present in vivo proof of efficacy data using several mouse models. Together with non-human primate studies, these data suggest that NI-1701 may be an effective and safe anticancer therapeutic both as a monotherapy and in combination. 
MATERIAL AND METHODS

Cell lines and primary samples
Reagents
NI-1701, CD47 monovalent Ab, CD19 monovalent Ab, and CD19/CD47 hi biAb were generated using a fixed Ig heavy chain variable domain (VH) library construction and produced as described in detail by Fischer et al. (18) . Human (h) IgG1 isotype-matched control mAb was produced and purified at
Novimmune from Chinese Hamster Ovary (CHO) culture supernatants. The CD19 monovalent Ab contains the same anti-CD19 arm as NI-1701 and an irrelevant nonbinding arm, while the CD47 monovalent Ab contains the same anti-CD47 arm as NI-1701 and an irrelevant nonbinding arm. The bivalent CD19 Ab (i.e., a mAb) contains the same anti-CD19 arm as NI-1701. The CD19/CD47 hi biAb contains the same anti-CD19 arm as NI-1701 and an anti-CD47 arm with a higher affinity than NI-1701 for CD47. Clinical-grade rituximab (anti-CD20 hIgG1 mAb) was obtained from FarmaMondo.
The neutralizing anti-hCD47 mAb mouse B6H12 was cloned and expressed as hIgG1 in CHO cells (hB6H12). The anti-CD47 mAb, 5F9 (20) , was cloned and expressed as hIgG4 in CHO cells. 
Whole blood binding
Human whole blood samples were collected from healthy donors in citrate at the Blood Transfusion Center in Geneva. Samples were mixed with 3 µg/mL of AF488-coupled NI-1701, hB6H12 or isotype control (using the Alexa Fluor 488 Protein Labeling Kit (A10235, Thermo Fisher Scientific)) and surface staining Abs for 30 min at 4°C. More precisely, samples were incubated with PE anti-hCD41a (#555467, BD Biosciences), APC-Cy7 anti-hCD3 (#557757, BD Biosciences) and with BV510 antihCD20 (#302311, BioLegend) Abs. Whole blood was then divided in two samples: 5 µL were diluted in PBS for erythrocytes analysis while 150 µL were incubated with erythrocyte lysing solution (#349202, BD Biosciences), and washed for leukocytes and platelets analysis. Samples were then acquired on a CytoFLEX instrument (Beckman Coulter) and analyzed with Flowjo® software.
Affinity measurements
The affinity (K D ) for the binding to CD19 was determined on a 3200 KinExA (Sapidyne) while the binding to CD47 was determined using Surface Plasmon Resonance (SPR) on a Biacore T200 instrument (GenScript). The affinity for CD19 was determined on CD19 + Raji B cells with a F(ab')2 of the CD19 arm, while the affinity for CD47 was determined using recombinant hCD47 protein with NI-1701. 
Antibody Dependent Cellular Phagocytosis
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats by Ficoll gradient. Classical macrophages (M0) were prepared as previously described (19) . M1 macrophages were generated from PBMCs with 20 ng/mL recombinant hMCSF for 14 days with the addition of 50 ng/mL of hIFNγ during the last 18h of culture. For M2a or M2c polarization, macrophages were generated from PBMCs supplemented with 20 ng/mL recombinant hMCSF for 14 days with the addition of either 20 ng/mL of hIL-4 or 10 ng/mL of hIL-10 + 20 ng/mL of hTGFβ during the last 18h of culture, respectively (21) (22) (23) . Target cells stained with 0.2 µM CFSE (Invitrogen) were opsonized with the tested Abs for 15 min at 37°C. The flow cytometry based phagocytosis assay used is described elsewhere (19) . In here, the ratio between effector (macrophages) and target cells was 1:5. 
Cell-derived xenograft model in mice
In accordance with the Swiss animal protection law, 5 x 10 6 Raji cells were injected subcutaneously into the flank of 6-to 10-week-old NOD/SCID mice (Charles River Laboratories). Tumor volume was measured using a caliper and calculated using the formula (width x length x height) x π/6. Mice 
Patient-derived xenograft model in mice
This experiment was performed in accordance with the United States animal protection law and Institutional animal guidelines. NSG mice irradiated 2 days earlier (275cGy) were injected i.v. with 
Statistical Analysis
GraphPad Prism 6 was used for all statistical analysis depicted in each figure legend. Data are expressed as mean ± SEM or mean ± SD, as indicated. 
RESULTS
The anti-CD19/CD47 biAb, NI-1701, specifically binds to B cells in whole blood
As CD47 is a ubiquitously expressed molecule (24, 25) , we designed a biAb, NI-1701, that consists of a CD47 binding arm with an affinity that affords rapid engagement/disengagement kinetics when binding CD47 in a monovalent setting. This arm is paired with a high affinity CD19 binding arm, in a fully human biAb, the κλ-body (18) . More precisely, the affinity to CD19 was measured to be subnanomolar (i.e. 0.6nM) while the affinity to CD47 is 500 nM. In order to assess the specificity of NI-1701, the binding profile to B cells was assessed in whole blood using flow cytometry. While CD47 is expressed on various cells in whole blood, including T cells, platelets and erythrocytes (Supplementary Table S1 ), NI-1701 substantially shifted the signal for binding only to the B cells and rather weakly if at all to platelets, T cells and erythrocytes as compared to the irrelevant isotype control (Fig. 1) . Conversely, the CD47 mAb, hB6H12, used as a control for CD47 expression, significantly bound to all cell populations (Fig. 1) . potency of phagocytosis as compared to NI-1701, with a 4.2-fold decrease for the CD19 monovalent Ab (EC 50 of 31.11 ng/mL) and a 52-fold decrease for the CD47 monovalent Ab (EC 50 of 385.3 ng/mL) ( Fig. 2A) . Interestingly, the bivalent CD19 Ab (containing the same anti-CD19 arm as NI-1701) induces similar potency to NI-1701 (i.e., EC 50 at 7.7 ng/mL), although less effective at inducing maximum phagocytosis (Fig.2A) .
In order to demonstrate the contribution of CD47/SIRPα interaction to phagocytosis, we generated Raji cells with a minimal expression level of CD47, while the levels of CD19 and CD20 remain unchanged (Fig. 2B) . We then assessed the activity of rituximab on the wt versus the CD47 silenced Raji cells. While rituximab mediated efficient phagocytosis of the wt Raji cells, the knockdown of CD47 on the target cell surface results in an enhanced potency of rituximab by 5 fold (Fig. 2C) , demonstrating that the reduction of the CD47/SIRPα interaction enhances CD20 mediated targeted cell killing. A similar result was seen with the CD19 monovalent Ab, in that silencing of CD47 enhanced Ab mediated phagocytosis. In contrast, and as expected, NI-1701 demonstrated a similar potency on both cell populations which was equal to the efficacy of the anti-CD19 monovalent Ab killing of CD47 silenced Raji cells (Fig. 2D) .
Next, the ability of NI-1701 and rituximab to mediate phagocytosis was compared using human (Fig. 3A) . NALM-6 cells, which express a low level of CD20 (Supplementary Table S2 ), were weakly phagocytosed in the presence of rituximab whereas NI-1701 mediated a potent effect (Fig. 3A) . SUDHL-4 cells were efficiently phagocytosed by both NI-1701 and rituximab, although the anti-CD20 mAb was slightly more effective ( Fig. 3A) , which may be explained by the high level of CD20 (Supplementary Table S2 ).
Using in vitro polarized macrophages to mimic the situation of the tumor microenvironment, the ability of NI-1701 to engage different subtypes of macrophages to mediate phagocytosis of cancer target cells was assessed. Classical M-CSF cultured macrophages (M0), M1 macrophages polarized using IFNγ as well as M2 phenotypes, defined as M2a and M2c, generated by the addition of IL-4 or IL-10 + TGFβ, respectively, were used. NI-1701 mediated a similar level of phagocytosis of Raji cells by all subsets of macrophages with up to 40 to 50% of the macrophages being phagocytic (Fig. 3B) 
Finally, as a fully human IgG1 Ab, we wanted to investigate whether NI-1701 was able to mediate other Fc-dependent effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC).
As expected, a dose-dependent killing by ADCC of Raji cells in the presence of NI-1701 was observed (Fig. 3C) .
NI-1701 controls tumor growth in vivo
We next sought to assess the in vivo anti-tumor killing efficacy of NI-1701 in a mouse xenograft model using NOD/SCID mice implanted with Raji cells. NI-1701 was significantly efficacious in controlling tumor growth, with a final tumor growth inhibition (TGI) of 79% as compared to the control (Fig. 4A, upper panel) . The monovalent variants of NI-1701, i.e., CD47 and CD19 monovalent Abs, showed a partial effect on tumor growth with a final TGI of 54% and 46%, respectively. The bivalent CD19 Ab only demonstrated a partial effect with a final TGI of 36%. Tumor growth was monitored beyond the end of the treatment period demonstrating that NI-1701 affords a longer period of slowing tumor growth compared with both monovalent Abs and the bivalent CD19 Ab (Fig. 4A, lower panel). These results confirmed that co-engaging both CD47 and CD19 by NI-1701 promotes a more potent antitumor effect.
Next, the activity of NI-1701 was compared to the anti-CD20 mAb, rituximab. Since combination therapies are widely used in oncology clinical practice we tested the hypothesis that targeting two different B cell epitopes in conjunction with blockade of the CD47/SIRPα interaction may lead to enhanced tumor control. As expected, rituximab significantly reduced tumor growth compared to hIgG1 control treated group (Fig. 4B, upper panel) . Interestingly, NI-1701 was superior to rituximab at reducing tumor growth (72% vs 48% of TGI for NI-1701 and rituximab, respectively). Finally, the combination therapy of NI-1701 and rituximab led to higher inhibition (92%) of tumor growth until the end of the treatment period at day 26. Tumor growth was monitored beyond the end of the treatment period and the data demonstrate that NI-1701 affords a longer period of slowing tumor growth than rituximab, and that the combination of the two resulted in a 2.45-fold increase in the survival time from a median of 24.5 days for isotype control treated animals to 60 days for the combination therapy treated group (Fig. 4B, lower panel) . 
NI-1701 demonstrates a favorable pharmacokinetic and safety profile in nonhuman primates
To evaluate PK and safety parameters, NI-1701 was administered to cynomolgus monkeys. The anti-CD19 arm of NI-1701 is not cross-reactive to cynomolgus monkey while the CD47 arm has a similar binding profile for cynomolgus monkey and human CD47. This allowed us to test the hypothesis that the affinity for CD47 was sufficiently low to circumvent potential liabilities of targeting the ubiquitously expressed CD47, i.e. rapid drug elimination kinetics through TMDD and target related toxicity including anemia. NI-1701 was administered once as an i.v. bolus, at a high (10 mg/kg) or low (0.5 mg/kg) dose, and serum concentrations of the compound were measured. The terminal elimination profile of NI-1701 was parallel for both doses, suggesting that no target mediated mechanisms contributed to the clearance of the biAb (Fig. 5A) . Furthermore, the PK parameter estimates for NI-1701, i.e., half-life and clearance, were 110h and 12.24 mL/day/kg, close to those of other hIgG1 molecules that have been reported during preclinical and clinical development (26) .
In order to evaluate the impact that a higher affinity binding to CD47 may have on Ab clearance, we compared the PK of NI-1701 with another bispecific molecule having the same (non-cross reactive) CD19 targeting arm but a CD47 blocking arm with a higher affinity (i.e., 100 nM), noted as CD19/CD47 hi biAb. NI-1701 and CD19/CD47 hi biAb have similar functional potency (Supplementary Figure S1) . The PK profile of the latter has been described elsewhere (19) . The two biAbs have similar half-lives (110h for NI-1701 and 106h for CD19/CD47 hi biAb) but the clearance parameters are different, with the CD19/CD47 hi biAb exhibiting a high clearance value (i.e., 18.24 mL/day/kg) as compared to 12.24 mL/day/kg for NI-1701. Examination of the distribution phase (i.e., alpha phase) of NI-1701 versus the CD19/CD47 hi biAb during the first 24 hours following i.v. bolus revealed that, at both high and low doses, the initial serum concentration measurements for NI-1701 were higher than for CD19/CD47 hi biAb (Fig. 5B) . This result suggests an early binding event which impacts the distribution phase and results in a higher clearance for the higher affinity CD47 binding molecule. The ratio of AUC 0-inf shows that an even greater proportion of CD19/CD47 hi biAb is undetected at the low dose versus the high dose compared with NI-1701 (59% at 0.5 mg/kg compared with 67% at 10 mg/kg), suggesting that a target mediated event occurs (Supplementary Table S3 ). Finally, while no hematological toxicity was observed, an increase in circulating IL-6 levels following CD19/CD47 hi biAb injection was detected (Fig. 5C ).
A DRF study was conducted with NI-1701 in cynomolgus monkeys where treated animals received 2 i.v. bolus injections at 30 mg/kg at weeks 1 and 2, followed by two injections at 100 mg/kg at weeks 3 Table S4 ). Furthermore, a minimal accumulation of NI-1701 was seen between the first and second injection at each dose level (Fig. 5D ).
No signs of anemia or thrombocytopenia were observed as red blood cell and platelet levels remained within normal ranges throughout the study (Fig. 5E ). There were no drug related observations. NI-1701 was well tolerated at doses up to 100 mg/kg. Complete haematological results from the study are tabulated in Supplementary Table S5 . Further in vitro safety assessments were performed on human and/or cynomolgus whole blood to assess hemaglutination and platelet aggregation, and no findings related to NI-1701 were observed whereas anti-CD47 mAbs showed effects on both parameters (Supplementary Figure S2A , B, C and D).
NI-1701 effectively kills primary leukemia and lymphoma cells
In order to demonstrate the clinical relevance of targeting CD47 on CD19 + cancer cells, the in vitro studies were extended to primary cells obtained from patients with B cell leukemias or lymphomas.
NI-1701 mediated an efficient and potent phagocytosis of primary cells from 24 individual CLL patients (Fig. 6A) . Imaging confirmed the engulfment of the target cells by visualizing the double labeling of the CD14 + phagocytes and the CFSE + target cells (Fig. 6B, left panel) . Calculating the phagocytic index revealed that a mean of 175 (+/-80) B-CLL cells opsonized with NI-1701 were phagocytized by every 100 macrophages (Fig. 6B, right panel) . Similar results were obtained with rituximab ( Fig. 6A and Fig. 6B ).
Cells from bone marrow aspirates of 12 and whole blood of 3 patients with B-ALL, a leukemia with limited treatment options, were also obtained and used in the ADCP assay. A significantly enhanced phagocytosis of target cells in the presence of NI-1701 was consistently observed with a maximum percentage of phagocytosis ranging from 46.4 to 86.3% and a mean value of 62.5% (+/-13.6). The activity of NI-1701 was three times higher than the isotype control and significantly higher than rituximab (43.26% +/-19.1) (Fig. 6A) . NI-1701 induced phagocytosis was also tested using samples purified B cells isolated from lymph node biopsies of 10 FL patients were used as target cells. NI-1701 and rituximab induced equivalent phagocytosis of these patients' FL B cells (Fig. 6C) .
Using a patient cell derived model (PDX) generated with PBMCs from a B-ALL patient, the ability of NI-1701 to kill primary tumor cells in vivo was evaluated. Mice were i.v. injected with patient-derived B-ALL cells, and 7 days later treated either with NI-1701 or isotype control Ab. Analysis of the bone marrow, peripheral blood, spleen and liver demonstrated that, while B-ALL cells were present in these compartments following hIgG1 control Ab treatment, NI-1701 eradicated the tumor burden (Fig. 6D) . higher affinity CD47-binding arm was tested in the biAb format (i.e., CD47/CD19) and administered to NHP. Interestingly, while no hematological toxicity was observed, the higher CD47 binding resulted in rapid decrease in initial plasma concentration (alpha phase). We hypothesize that this drop in the alpha phase concentration is due to a binding event in blood leading to a faster clearance, which is supported by our in vitro observation in whole blood demonstrating increased binding to erythrocytes and platelets. Furthermore, these data corroborate previous published results of a biAb with reduced affinity for CD47 which allows for selective binding to dual antigen-expressing cells in the presence of a large CD47-sink (32) . Finally, the lower affinity CD47-binding arm of NI-1701 was far less prone to inducing cytokine release in vitro as compared to the CD19/CD47 hi BiAb. Taken together, the selectivity afforded by the high affinity CD19-binding arm coupled to a low affinity CD47-binding arm has the potential to significantly widen the safety margin of therapeutic CD47 targeting in patients. Mice were euthanized when the endpoint was reached (tumor volume ≈ 1400mm 3 ) or at the end of the study (day 60). For comparison of survival curves (Kaplan Meier curves), a log-rank (Mantel-Cox) test was performed. p< 0.05 is considered to be statistically significant. Primary samples were treated with 10μg/ml of hIgG1 control, NI-1701 or rituximab (RTX). 
